The global orthobiologics market was valued at $4,870 million in 2017 and is projected to reach $6,870 million by 2025, registering a CAGR of 4.3% from 2018 to 2025.
Orthobiologics are substances, found in human body, used for faster healing process of injuries, such as broken bones, injured muscles, and ligaments. These substances are made up of substances found in human body. When orthobiologics are used in higher concentration, they help accelerate healing process and thus reduce the number of hospital visits.
Increase in demand for advanced treatment, rise in prevalence of osteoarthritis, degenerative arthritis, spinal injuries, and soft tissue injuries boost the growth of the orthobiologics market In addition, rise in road accidents & sports injuries, surge in obesity rate, awareness among patients, and rapidly aging population drive the growth of the global orthobiologics market. However, high cost of procedures, and stringent regulatory approval procedures restrain the growth of this market. Advancements in implant technologies and rise in demand for biological solutions as compared to mechanical solutions create opportunities for the growth of the market.
The global orthobiologics market is segmented based on product, application, type, end user, and region. Based on product, the market is classified into demineralized bone matrix (DBM), allograft, bone morphogenetic protein (BMP), Viscosupplementation products, synthetic bone substitutes, and others. Based on type, the market is categorized into knee, ankle, hip, wrist & shoulder, spine, and others. Based on end user, the market is divided into hospitals & ambulatory centers, research & academic institute, and dental clinics. Based on application, the market is further fragmented into osteoarthritis & degenerative arthritis, spinal fusion, fracture recovery, soft tissue injuries, and maxillofacial & dental applications.
Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
KEY MARKET SEGMENTS
By Product
By Type
By Application
By End User
By Region
o Canada
o Mexico
o France
o UK
o Italy
o Spain
o Rest of Europe
o China
o Japan
o Australia
o South Korea
o Rest of Asia-Pacific
o South Africa
o Saudi Arabia
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
Orthobiologics are substances, found in human body, used for faster healing process of injuries, such as broken bones, injured muscles, and ligaments. These substances are made up of substances found in human body. When orthobiologics are used in higher concentration, they help accelerate healing process and thus reduce the number of hospital visits.
Increase in demand for advanced treatment, rise in prevalence of osteoarthritis, degenerative arthritis, spinal injuries, and soft tissue injuries boost the growth of the orthobiologics market In addition, rise in road accidents & sports injuries, surge in obesity rate, awareness among patients, and rapidly aging population drive the growth of the global orthobiologics market. However, high cost of procedures, and stringent regulatory approval procedures restrain the growth of this market. Advancements in implant technologies and rise in demand for biological solutions as compared to mechanical solutions create opportunities for the growth of the market.
The global orthobiologics market is segmented based on product, application, type, end user, and region. Based on product, the market is classified into demineralized bone matrix (DBM), allograft, bone morphogenetic protein (BMP), Viscosupplementation products, synthetic bone substitutes, and others. Based on type, the market is categorized into knee, ankle, hip, wrist & shoulder, spine, and others. Based on end user, the market is divided into hospitals & ambulatory centers, research & academic institute, and dental clinics. Based on application, the market is further fragmented into osteoarthritis & degenerative arthritis, spinal fusion, fracture recovery, soft tissue injuries, and maxillofacial & dental applications.
Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
- A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Product
- Demineralized Bone Matrix (DBM)
- Allograft
- Bone Morphogenetic Protein (BMP)
- Viscosupplementation Products
- Synthetic Bone Substitutes
- Others
By Type
- Knee
- Ankle
- Hip
- Wrist & Shoulder
- Spine
- Others
By Application
- Osteoarthritis & Degenerative Arthritis
- Spinal Fusion
- Fracture Recovery
- Soft Tissue Injuries
- Maxillofacial & Dental Applications
By End User
- Hospitals & Ambulatory Centers
- Research & Academic Institute
- Dental Clinics
By Region
- North America
o Canada
o Mexico
- Europe
o France
o UK
o Italy
o Spain
o Rest of Europe
- Asia-Pacific
o China
o Japan
o Australia
o South Korea
o Rest of Asia-Pacific
- LAMEA
o South Africa
o Saudi Arabia
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
- Arthrex, Inc. (Arthrex)
- Exactec Inc.
- Globus Medical, Inc.
- Integra LifeSciences Holdings Corporation
- Johnson and Johnson (J&J)
- Medline Industries, Inc.
- NuVasive Inc.
- Stryker Corporation
- Wright Medical Group, Inc.
- Zimmer Biomet Holdings, Inc.,
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
- Kuros Biosciences AG
- XTANT MEDICAL
- Bioventus
Frequently Asked Questions about the Global Orthobiologics Market
What is the estimated value of the Global Orthobiologics Market?
What is the growth rate of the Global Orthobiologics Market?
What is the forecasted size of the Global Orthobiologics Market?
Note: Product cover images may vary from those shown
Chapter 1: INTRODUCTION
Chapter 2: EXECUTIVE SUMMARY
Chapter 3: MARKET OVERVIEW
Chapter 4: ORTHOBIOLOGICS MARKET, BY PRODUCT
Chapter 5: ORTHOBIOLOGICS MARKET, BY APPLICATION
Chapter 6: ORTHOBIOLOGICS MARKET, BY TYPE
Chapter 7: ORTHOBIOLOGICS MARKET, BY END USER
Chapter 8: GLOBAL ORTHOBIOLOGICS MARKET, BY REGION
Chapter 9: COMPANY PROFILES
Note: Product cover images may vary from those shown
According to this report titled, 'Orthobiologics Market by Product, Application, Type, and End User: Global Opportunity Analysis and Industry Forecast, 2018 - 2025,' the market was valued at $4,870 million in 2017, and is projected to reach $6,870 million by 2025, growing at a CAGR of 4.3% from 2018 to 2025.
Orthobiologics are substances that orthopedic surgeons utilize to help injuries heal more quickly. These products are made from substances that are naturally found in human body. These are used to improve the healing of broken bones and injured muscles, tendons, and ligaments.
The key factors that drive the growth of the global orthobiologics market are increase demand for advanced treatment and rise in prevalence of osteoarthritis, degenerative arthritis, spinal injuries, and soft tissue injuries majorly drive the growth of the market. Further, rise in obesity rate, growth in awareness among the patients, and increase in geriatric population supports the market growth. However, high cost of procedures and stringent regulatory approval process restrict the growth of this market. Advancements in implant technologies and growth in demand for biological solutions create opportunities for market growth.
The global orthobiologics market is segmented based on product, application, type, end user, and region. Based on product, the market is classified into demineralized bone matrix (DBM), allograft, bone morphogenetic protein (BMP), viscosupplementation products, synthetic bone substitutes, and others. Viscosupplementation products is the largest and the fastest growing segment. This is due to its application for treatment of knee pain associated with osteoarthritis. Increase in geriatric population, rise in prevalence of osteoarthritis, and growth in lifestyle-induced disorders, such as obesity, drive the adoption of viscosupplement products.
Based on type, the market is categorized into knee, ankle, hip, wrist & shoulder, spine, and others. The knee segment held largest share in the market in 2017; this is due to rise in number of aged patients undergoing knee replacement procedures. Spine is the fastest growing segment due to rise in number of sports related injuries to the spine.
Based on application, the market is categorized into application such as osteoarthritis & degenerative arthritis, spinal fusion, fracture recovery, soft tissue injuries, maxillofacial, and dental applications. Osteoarthritis & degenerative arthritis is the largest segment due to increase in prevalence of these conditions. Spinal fusion was the fastest growing segment in 2017 owing to the benefits offered by orthobiologics in the treatment.
Based on end user, the market is categorized into hospitals & ambulatory centers, research & academic institute, and dental clinics. The hospitals & ambulatory centers segment held largest share in the market in 2017 and is the fastest growing segment as these facilities are fully equipped for performing the surgeries and have the skilled professionals to carry out the procedures.
Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Key Findings of the Orthobiologics Market:
North America occupied more than half of the share of global orthobiologics market in 2017.
The spinal fusion segment is anticipated to grow with a CAGR of 4.9% during the forecast period.
The knee segment accounted for more than one-thirds share of the market in 2017.
Asia Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.
North America was the leading revenue contributor to the global market in 2017, garnering nearly more than half of the total market share, owing to high purchasing power, rise in the elderly population, favorable reimbursement rates, increase in the prevalence of orthopedic disorders even among younger population, and surge in number of road & sports However, Asia-Pacific is expected to grow at the highest CAGR of 5.7% from 2018 to 2025, owing to increase in disposable income; surge in obesity, sports related accidents; and rise in awareness related to different orthobiologics.
The report provides an extensive competitive analysis and profiles of the key market players such as Stryker Corporation, Zimmer Biomet Holdings, Inc., Wright Medical Group, Inc., Integra LifeSciences Holdings Corporation, Arthrex, Inc. (Arthrex), Johnson and Johnson (J&J), Exactec Inc., Medline Industries, Inc., Globus Medical, Inc., and NuVasive Inc.
Orthobiologics are substances that orthopedic surgeons utilize to help injuries heal more quickly. These products are made from substances that are naturally found in human body. These are used to improve the healing of broken bones and injured muscles, tendons, and ligaments.
The key factors that drive the growth of the global orthobiologics market are increase demand for advanced treatment and rise in prevalence of osteoarthritis, degenerative arthritis, spinal injuries, and soft tissue injuries majorly drive the growth of the market. Further, rise in obesity rate, growth in awareness among the patients, and increase in geriatric population supports the market growth. However, high cost of procedures and stringent regulatory approval process restrict the growth of this market. Advancements in implant technologies and growth in demand for biological solutions create opportunities for market growth.
The global orthobiologics market is segmented based on product, application, type, end user, and region. Based on product, the market is classified into demineralized bone matrix (DBM), allograft, bone morphogenetic protein (BMP), viscosupplementation products, synthetic bone substitutes, and others. Viscosupplementation products is the largest and the fastest growing segment. This is due to its application for treatment of knee pain associated with osteoarthritis. Increase in geriatric population, rise in prevalence of osteoarthritis, and growth in lifestyle-induced disorders, such as obesity, drive the adoption of viscosupplement products.
Based on type, the market is categorized into knee, ankle, hip, wrist & shoulder, spine, and others. The knee segment held largest share in the market in 2017; this is due to rise in number of aged patients undergoing knee replacement procedures. Spine is the fastest growing segment due to rise in number of sports related injuries to the spine.
Based on application, the market is categorized into application such as osteoarthritis & degenerative arthritis, spinal fusion, fracture recovery, soft tissue injuries, maxillofacial, and dental applications. Osteoarthritis & degenerative arthritis is the largest segment due to increase in prevalence of these conditions. Spinal fusion was the fastest growing segment in 2017 owing to the benefits offered by orthobiologics in the treatment.
Based on end user, the market is categorized into hospitals & ambulatory centers, research & academic institute, and dental clinics. The hospitals & ambulatory centers segment held largest share in the market in 2017 and is the fastest growing segment as these facilities are fully equipped for performing the surgeries and have the skilled professionals to carry out the procedures.
Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Key Findings of the Orthobiologics Market:
North America occupied more than half of the share of global orthobiologics market in 2017.
The spinal fusion segment is anticipated to grow with a CAGR of 4.9% during the forecast period.
The knee segment accounted for more than one-thirds share of the market in 2017.
Asia Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.
North America was the leading revenue contributor to the global market in 2017, garnering nearly more than half of the total market share, owing to high purchasing power, rise in the elderly population, favorable reimbursement rates, increase in the prevalence of orthopedic disorders even among younger population, and surge in number of road & sports However, Asia-Pacific is expected to grow at the highest CAGR of 5.7% from 2018 to 2025, owing to increase in disposable income; surge in obesity, sports related accidents; and rise in awareness related to different orthobiologics.
The report provides an extensive competitive analysis and profiles of the key market players such as Stryker Corporation, Zimmer Biomet Holdings, Inc., Wright Medical Group, Inc., Integra LifeSciences Holdings Corporation, Arthrex, Inc. (Arthrex), Johnson and Johnson (J&J), Exactec Inc., Medline Industries, Inc., Globus Medical, Inc., and NuVasive Inc.
Note: Product cover images may vary from those shown
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
